<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852708</url>
  </required_header>
  <id_info>
    <org_study_id>12-014-NPT</org_study_id>
    <nct_id>NCT01852708</nct_id>
  </id_info>
  <brief_title>Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood</brief_title>
  <acronym>MAPS</acronym>
  <official_title>Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Natera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Natera, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect maternal blood samples from pregnant women carrying a
      fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including
      microdeletions in order to further develop a non-invasive prenatal screening test based on
      fetal DNA isolated from maternal blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to further develop a non-invasive prenatal blood test that can
      diagnose genetic disorders in the fetus by looking at fetal DNA (genetic material) found in
      the mother's bloodstream during pregnancy.

      Women carrying a fetus diagnosed with microdeletions/microduplications (small missing or
      extra pieces of DNA that can cause problems), aneuploidy (trisomy 21, 18, or 13) or other
      genetic disorders will be asked to participate.

      If this study is successful, it will reduce the need for invasive procedures during pregnancy
      such as amniocentesis and chorionic villus sampling (CVS) but still enable women to find out
      accurate information regarding their baby's health early in the pregnancy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity of testing</measure>
    <time_frame>1 year</time_frame>
    <description>Sensitivity and Specificity of the test to diagnose microdeletions (eg. 22q and 5p-) and aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Trisomy 21</condition>
  <condition>Trisomy 18</condition>
  <condition>Trisomy 13</condition>
  <condition>Sex Chromosome Abnormalities</condition>
  <condition>Microdeletion Syndromes</condition>
  <arm_group>
    <arm_group_label>Pregnant Women</arm_group_label>
    <description>Women and their partners (presumed biological father of the fetus) who are currently pregnant and carrying a fetus that has been diagnosed with a microdeletion/duplication syndrome, aneuploidy or another genetic disorder (positive karyotype result or positive result on microarray test).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The mother and biological father (if available) will be asked to provide a blood sample.
      There will be up to 4 tubes collected from the mother (approximately 3 tablespoons) and 1
      tube collected from the father (2 teaspoons). The father may instead provide a saliva or
      buccal sample.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older at enrollment

          -  Gestation age of at least 9 weeks, 0 days by best obstetrical estimate

          -  One or more fetuses with a clinically confirmed diagnosis of a genetic variant of
             interest via karyotype, FISH, chromosomal microarray or other genetic assay AND/OR

          -  One or more fetuses with any variant of fetal structure that is expected to require
             medical or surgical intervention in the newborn period, shorten lifespan, affect
             intellectual development or otherwise indicate a genetic anomaly AND/OR

          -  Positive high risk noninvasive prenatal screening or serum screening result

          -  Able to provide informed consent

        Exclusion Criteria:

        â€¢Maternal history of bone marrow or organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachary Demko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Natera, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Egbert</last_name>
    <phone>650-249-9090</phone>
    <phone_ext>696</phone_ext>
    <email>research@natera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Lee</last_name>
    <phone>650-249-9090</phone>
    <phone_ext>1913</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Natera, Inc.</name>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <zip>94070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Lee</last_name>
      <phone>650-249-9090</phone>
      <phone_ext>1913</phone_ext>
      <email>alee@natera.com</email>
    </contact>
    <investigator>
      <last_name>Zachary Demko, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MFM Group of Southern CA</name>
      <address>
        <city>San Gabriel</city>
        <state>California</state>
        <zip>91776</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington Women's Wellness Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Meltzer Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Materno Infantil Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alba Farras Llobet</last_name>
      <phone>34620349753</phone>
    </contact>
    <investigator>
      <last_name>Elena Carreras Moratonas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GenePhile Biosciences</name>
      <address>
        <city>Taipei</city>
        <zip>10050</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2013</study_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>22q</keyword>
  <keyword>1p36</keyword>
  <keyword>Angelman</keyword>
  <keyword>Cri-du-chat</keyword>
  <keyword>Prader-Willi</keyword>
  <keyword>DiGeorge</keyword>
  <keyword>Turner syndrome</keyword>
  <keyword>Patau syndrome</keyword>
  <keyword>Edwards syndrome</keyword>
  <keyword>Down syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Trisomy 13 Syndrome</mesh_term>
    <mesh_term>Trisomy 18 Syndrome</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Trisomy</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
    <mesh_term>Sex Chromosome Aberrations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

